作者: Surasawadee Ausavarat , Jiraporn Sriprapaporn , Busara Satayaban , Wanna Thongnoppakhun , Aunchalee Laipiriyakun
DOI: 10.1186/S13044-015-0024-4
关键词:
摘要: Circulating thyrotropin receptor messenger ribonucleic acid (TSHR mRNA) assay has been validated in the follow-up of differentiated thyroid carcinoma (DTC) because its high sensitivity during hormone therapy and no interference with endogenous anti-thyroglobulin antibodies (TgAb) compared to serum thyroglobulin (Tg). We investigated efficacy TSHR mRNA 160 DTC patients using quantitative PCR (qPCR). Only level structural persistent disease TgAb-positive (3.47 (2.97–9.53) pg equivalents/μg total RNA; p = 0.013) subgroup distant metastasis (5.55 (3.28–12.52) p = 0.009) were significantly different from evidence (2.32 (1.44–3.94) RNA). Applying cutoff at 2.00 pg RNA enabled us predict a 62.3 % specificity 42.9 %. Although, TgAb-postive (88.2 %) was superior than Tg (47.1 %) (p = 0.00002), accuracy test is only 54.5 %. This study demonstrated that good but it neither specific enough as first-line testing nor surrogate marker our patients.